Acute Graft Versus Host Disease [GvHD] Treatment Market Insights, 2021-2031

Acute Graft Versus Host Disease [GvHD] Treatment Market (Drug Class: Corticosteroids, Immunosuppressive Agents, Biological Therapy, Kinase Inhibitors, Monoclonal Antibody, Mesenchymal Stem Cell [MSC], and Others; Route of Administration: Oral, Topical, and Intravenous; and Distributing Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Ruxolitinib Gains Recognition for At-home Treatment amid COVID-19 Crisis

In response to the public health emergency posed by the COVID-19 pandemic, National Health Service (NHS) England and NHS Improvement have established a rapid policy development process to aid clinicians in offering best care and advice to patients with high risk of coronavirus. This has led to awareness about ruxolitinib, which is found to be effective in treating acute graft versus host disease (GvHD) patients who have not responded to steroids. Ruxolitinib is a tablet that can be consumed at home, which eliminates the need for a patient to visit hospital frequently and reduce the risk of contracting COVID-19.

Companies in the acute graft versus host disease (GvHD) treatment market are increasing their output capacities and maintaining steady supply for ruxolitinib as an alternative treatment option, which is reducing the need to attend hospital unless adverse events occur.

These factors are anticipated to drive the acute graft versus host disease (GvHD) treatment market during the forecast period.

acute graft versus host disease (gvhd) treatment market infographic

To know the scope of our report Get a Sample on Acute Graft Versus Host Disease [GvHD] Treatment Market

Corticosteroids Associated with Adverse Effects, Dismal Patient Outcomes

Clinically significant GvHD occurs frequently in spite of prophylaxis, which has led to the demand for corticosteroids as the mainstay of frontline therapy. However, in many cases, these drugs can have severe adverse effects and outcomes are dismal in patients who historically have had limited treatment options. Such findings are affecting the growth of the global acute graft versus host disease (GvHD) treatment market. Hence, companies in the acute graft versus host disease (GvHD) treatment market are boosting their R&D capabilities to successfully manufacture drugs that can be administered in a multicenter environment.

Get a glimpse of the in-depth analysis through our Report Brochure

Ruxolitinib Helps Overcome Steroid Resistance Found in GvHD Patients

Steroid resistance has been found in GvHD patients. This condition is difficult to treat and associated with a high mortality rate. In order to overcome these issues, companies in the acute graft versus host disease (GvHD) treatment market are boosting their output capacities for Ruxolitinib. This tablet holds promising potential as a treatment option for patients with steroid-refractory aGvHD after allogeneic hematopoietic stem cell transplantation.

Ruxolitinib tablet works by blocking the action of enzymes known as Janus kinases (JAKs) that are involved in the production and growth of blood cells & immune function. By blocking JAKs, ruxolitinib reduces the abnormal production of blood cells, which helps to reduce the symptoms of GvHD. This tablet helps to address the side effects linked with the consumption of steroids.

Manufacturers Increase Research in Orphan Drugs to Prevent GI Diseases

The gastrointestinal damage is a leading cause of death in patients with acute GvHD. The clinical stage biopharmaceutical company VectivBio Holding AG is gaining cognizance about this condition and has received the FDA orphan drug designation for apraglutide, a next-generation, long-acting GLP-2 analog being developed for rare gastrointestinal (GI) diseases for the prevention of aGVHD. Companies in the acute graft versus host disease (GvHD) treatment market are gaining knowledge about such drug innovations and increasing their research capabilities.

Preclinical and clinical studies evaluating apraglutide & GLP-2 analogs in aGvHD indicate that apraglutide’s regenerative and anti-inflammatory effects on the GI tract may help to significantly reduce morbidity and mortality in patients suffering from intestinal GvHD.

acute graft versus host disease (gvhd) treatment market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

The ruxolitinib tablet is helping to avoid the need for urgent hospitalization in high-risk patients during the ongoing COVID-19 outbreak. The acute graft versus host disease (GvHD) treatment market is slated to clock a favorable CAGR of 8.6% during the forecast period. However, the high prevalence of steroid resistance has been found in GvHD patients. Hence, companies in the acute graft versus host disease (GvHD) treatment market should boost their production for ruxolitinib, which helps to improve outcomes in patient with steroid-refractory aGvHD after the allogeneic hematopoietic stem cell transplantation. As such, the acute graft versus host disease (GvHD) treatment market is expected to reach US$ 634.3 Mn by 2031.

Acute Graft Versus Host Disease (GvHD) Treatment Market: Overview

  • This report analyzes the current and future prospects of the global acute graft versus host disease (GvHD) treatment market. Focus on research & development and growth of the pharmaceutical industry are the key factors projected to fuel the growth of the global acute graft versus host disease (GvHD) treatment market during the forecast period.
  • The report provides an elaborate executive summary, which comprises a snapshot of the various segments of the global acute graft versus host disease (GvHD) treatment market. The report also provides information and data analysis of the global acute graft versus host disease (GvHD) treatment market about segments based on drug class, route of administration, distribution channel, and region.
  • The overview section of the report provides detailed qualitative analysis of drivers and restraints affecting the global acute graft versus host disease (GvHD) treatment market, along with opportunities in the global market
  • Additionally, the global acute graft versus host disease (GvHD) treatment market report includes company profiles and competitive matrix, which provide data about their businesses, product portfolios, and competitive landscape in the global acute graft versus host disease (GvHD) treatment market
  • The report includes data analysis on the global acute graft versus host disease (GvHD) treatment market attractiveness by region and segments
  • The last section of the report provides quantitative and qualitative analysis on market share of key players operating in the global acute graft versus host disease (GvHD) treatment market. It elaborates on the key competitive strategies adopted by the major industry players, thereby presenting a thorough understanding of the competitive scenario in the global acute graft versus host disease (GvHD) treatment market.

Acute Graft Versus Host Disease (GvHD) Treatment Market: Key Segments

  • In terms of drug class, the global acute graft versus host disease (GvHD) treatment market has been classified into corticosteroids, immunosuppressive agents, biological therapy, kinase inhibitors, monoclonal antibody, mesenchymal stem cell (MSC), and others
  • Based on route of administration, the global acute graft versus host disease (GvHD) treatment market has been categorized into oral, topical, and intravenous
  • In terms of distribution channel, the global acute graft versus host disease (GvHD) treatment market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment is likely to dominate the global acute graft versus host disease (GvHD) treatment market during the forecast period.
  • The market size and forecast for each of these segments have been provided from 2017 to 2031. The CAGR of respective segment has also been provided for the forecast period from 2021 to 2031, considering 2020 as the base year.

Acute Graft Versus Host Disease (GvHD) Treatment Market: Regional Outlook

  • In terms of region, the global acute graft versus host disease (GvHD) treatment market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, Spain, Italy, France, and Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, and Rest of Middle East & Africa)
  • The report provides market size and forecast for each region and country/sub-region from 2017 to 2031. Compound annual growth rate (CAGR) of each of these regions and countries have also been provided for the forecast period from 2021 to 2031, considering 2020 as the base year. The acute graft versus host disease (GvHD) treatment market study also covers the competitive scenario in these regions.

Companies Mentioned in Report

  • Key players in the global acute graft versus host disease (GvHD) treatment market have been profiled based on key aspects such as company overview, product portfolio, financial overview, recent developments, and competitive business strategies
  • Major companies profiled in the global acute graft versus host disease (GvHD) treatment market report are
    • Bristol-Myers Squibb
    • Novartis AG
    • Mesoblast Ltd.
    • Equillium, Inc.
    • Cynata Therapeutics Limited
    • MaaT Pharma
    • Incyte Corporation
    • Xenikos B.V.
    • Merck & Co. (OncoImmune, Inc.)
    • medac GmbH
    • CSL Limited

Acute Graft Versus Host Disease (GvHD) Treatment Market – Segmentation

Drug Class
  • Corticosteroids
  • Immunosuppressive Agents
  • Biological Therapy
  • Kinase Inhibitors
  • Monoclonal Antibody
  • Mesenchymal Stem Cell (MSC)
  • Others
Route of Administration
  • Oral
  • Topical
  • Intravenous
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of acute graft versus host disease treatment market?

Acute graft versus host disease treatment market is expected to reach US$ 634.3 Mn by 2031

What is the anticipated CAGR of the acute graft versus host disease treatment market in the forecast period?

Acute graft versus host disease treatment market is slated to clock a favorable CAGR of 8.6% during 2021-2031

What are the key driving factors for the growth of the acute graft versus host disease treatment market?

Acute graft versus host disease treatment market is driven by rise in focus on introducing novel effective therapeutics to address the unmet medical needs

Which region is expected to project the highest market share in the global acute graft versus host disease treatment market?

North America accounted for a major share of the global acute graft versus host disease (GvHD) treatment market during the forecast period

Who are the key players in the acute graft versus host disease treatment market?

Key players in the global acute graft versus host disease treatment market include Bristol-Myers Squibb, Novartis AG, Mesoblast Ltd., Equillium, Inc., Cynata Therapeutics Limited

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Acute Graft Versus Host Disease (GvHD) Treatment Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Segment Definitions

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast, 2017–2031

    5. Key Insights

        5.1. COVID-19 Pandemics Impact on Industry (value chain and short / mid / long term impact)

        5.2. Key Industry Events

        5.3. Pipeline Analysis

        5.4. Overview of Companies Offering stem cell treatment and/or Treg cell treatment for Acute Graft Versus Host Disease (GvHD)

        5.5. Treatment and Management of Acute Graft Versus Host Disease (aGvHD)

    6. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast, by Drug Class

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017–2031

            6.3.1. Corticosteroids

            6.3.2. Immunosuppressive Agents

            6.3.3. Biological Therapy

            6.3.4. Kinase Inhibitors

            6.3.5. Monoclonal Antibody

            6.3.6. Mesenchymal Stem Cell (MSC)

            6.3.7. Others

        6.4. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class

    7. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast, by Route of Administration

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017–2031

            7.3.1. Oral

            7.3.2. Topical

            7.3.3. Intravenous

        7.4. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration

    8. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast, by Distribution Channel

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017–2031

            8.3.1. Hospital Pharmacies

            8.3.2. Retail Pharmacies

            8.3.3. Online Pharmacies

        8.4. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel

    9. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Region

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Country/Region

    10. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017–2031

            10.2.1. Corticosteroids

            10.2.2. Immunosuppressive Agents

            10.2.3. Biological Therapy

            10.2.4. Kinase Inhibitor

            10.2.5. Monoclonal Antibody

            10.2.6. Mesenchymal Stem Cell (MSC)

            10.2.7. Others

        10.3. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017–2031

            10.3.1. Oral

            10.3.2. Topical

            10.3.3. Intravenous

        10.4. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017–2031

            10.4.1. Hospital Pharmacies

            10.4.2. Retail Pharmacies

            10.4.3. Online Pharmacies

        10.5. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Country, 2017–2031

            10.5.1. U.S.

            10.5.2. Canada

        10.6. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis

            10.6.1. By Drug Class

            10.6.2. By Route of Administration

            10.6.3. By Distribution Channel

            10.6.4. By Country

    11. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017–2031

            11.2.1. Corticosteroids

            11.2.2. Immunosuppressive Agents

            11.2.3. Biological Therapy

            11.2.4. Kinase Inhibitors

            11.2.5. Monoclonal Antibody

            11.2.6. Mesenchymal Stem Cell (MSC)

            11.2.7. Others

        11.3. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017–2031

            11.3.1. Oral

            11.3.2. Topical

            11.3.3. Intravenous

        11.4. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017–2031

            11.4.1. Hospital Pharmacies

            11.4.2. Retail Pharmacies

            11.4.3. Online Pharmacies

        11.5. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Country/Sub-region, 2017–2031

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Italy

            11.5.5. Spain

            11.5.6. Rest of Europe

        11.6. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis

            11.6.1. By Drug Class

            11.6.2. By Route of Administration

            11.6.3. By Distribution Channel

            11.6.4. By Country/Sub-region

    12. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017–2031

            12.2.1. Corticosteroids

            12.2.2. Immunosuppressive Agents

            12.2.3. Biological Therapy

            12.2.4. Kinase Inhibitors

            12.2.5. Monoclonal Antibody

            12.2.6. Mesenchymal Stem Cell (MSC)

            12.2.7. Others

        12.3. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017–2031

            12.3.1. Oral

            12.3.2. Topical

            12.3.3. Intravenous

        12.4. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017–2031

            12.4.1. Hospital Pharmacies

            12.4.2. Retail Pharmacies

            12.4.3. Online Pharmacies

        12.5. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Country/Sub-region, 2017–2031

            12.5.1. Japan

            12.5.2. China

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis

            12.6.1. By Drug Class

            12.6.2. By Route of Administration

            12.6.3. By Distribution Channel

            12.6.4. By Country/Sub-region

    13. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017–2031

            13.2.1. Corticosteroids

            13.2.2. Immunosuppressive Agents

            13.2.3. Biological Therapy

            13.2.4. Kinase Inhibitors

            13.2.5. Monoclonal Antibody

            13.2.6. Mesenchymal Stem Cell (MSC)

            13.2.7. Others

        13.3. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017–2031

            13.3.1. Oral

            13.3.2. Topical

            13.3.3. Intravenous

        13.4. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017–2031

            13.4.1. Hospital Pharmacies

            13.4.2. Retail Pharmacies

            13.4.3. Online Pharmacies

        13.5. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Country/Sub-region, 2017–2031

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis

            13.6.1. By Drug Class

            13.6.2. By Route of Administration

            13.6.3. By Distribution Channel

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017–2031

            14.2.1. Corticosteroids

            14.2.2. Immunosuppressive Agents

            14.2.3. Biological Therapy

            14.2.4. Kinase Inhibitors

            14.2.5. Monoclonal Antibody

            14.2.6. Mesenchymal Stem Cell (MSC)

            14.2.7. Others

        14.3. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017–2031

            14.3.1. Oral

            14.3.2. Topical

            14.3.3. Intravenous

        14.4. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017–2031

            14.4.1. Hospital Pharmacies

            14.4.2. Retail Pharmacies

            14.4.3. Online Pharmacies

        14.5. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Country/Sub-region, 2017–2031

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis

            14.6.1. By Drug Class

            14.6.2. By Route of Administration

            14.6.3. By Distribution Channel

            14.6.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competition Matrix (by tier and size of companies)

        15.2. Market Ranking, by Company, 2020

        15.3. Company Profiles

            15.3.1. Bristol-Myers Squibb

                15.3.1.1. Company Description

                15.3.1.2. Business Overview

                15.3.1.3. Strategic Overview

                15.3.1.4. SWOT Analysis

            15.3.2. Novartis AG

                15.3.2.1. Company Description

                15.3.2.2. Business Overview

                15.3.2.3. Strategic Overview

                15.3.2.4. SWOT Analysis

            15.3.3. Mesoblast Ltd

                15.3.3.1. Company Description

                15.3.3.2. Business Overview

                15.3.3.3. Strategic Overview

                15.3.3.4. SWOT Analysis

            15.3.4. Equillium, Inc.

                15.3.4.1. Company Description

                15.3.4.2. Strategic Overview

                15.3.4.3. SWOT Analysis

            15.3.5. Cynata Therapeutics Limited

                15.3.5.1. Company Description

                15.3.5.2. Business Overview

                15.3.5.3. Strategic Overview

                15.3.5.4. SWOT Analysis

            15.3.6. MaaT Pharma

                15.3.6.1. Company Description

                15.3.6.2. Strategic Overview

                15.3.6.3. SWOT Analysis

            15.3.7. Incyte Corporation

                15.3.7.1. Company Description

                15.3.7.2. Business Overview

                15.3.7.3. Strategic Overview

                15.3.7.4. SWOT Analysis

            15.3.8. Xenikos B.V.

                15.3.8.1. Company Description

                15.3.8.2. Strategic Overview

                15.3.8.3. SWOT Analysis

            15.3.9. Merck & Co. (OncoImmune, Inc.)

                15.3.9.1. Company Description

                15.3.9.2. Business Overview

                15.3.9.3. Strategic Overview

                15.3.9.4. SWOT Analysis

            15.3.10. medac GmbH

                15.3.10.1. Company Description

                15.3.10.2. SWOT Analysis

            15.3.11. CSL Limited

                15.3.11.1. Company Description

                15.3.11.2. Business Overview

                15.3.11.3. SWOT Analysis

    List of Tables

    Table 01: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031 (1/2)

    Table 02: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031 (2/2)

    Table 03: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 04: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 05: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 06: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 07: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 08: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 09: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 10: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 11: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 12: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 13: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 14: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 15: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 16: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 17: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 18: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 19: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 20: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 21: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 22: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 23: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 24: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 25: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    List of Figures

    Figure 01: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share, by Drug Class, 2020

    Figure 03: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share, by Route of Administration, 2020

    Figure 04: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share, by Distribution Channel, 2020

    Figure 05: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share, by Region, 2020

    Figure 06: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Drug Class, 2020 and 2031

    Figure 07: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class, 2021–2031

    Figure 08: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Corticosteroids, 2017–2031

    Figure 09: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Immunosuppressive Agents, 2017–2031

    Figure 10: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Biological Therapy, 2017–2031

    Figure 11: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Kinase Inhibitors, 2017–2031

    Figure 12: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Monoclonal Antibody, 2017–2031

    Figure 13: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Mesenchymal Stem Cell, 2017–2031

    Figure 14: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Others, 2017–2031

    Figure 15: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031

    Figure 16: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031

    Figure 17: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Oral, 2017–2031

    Figure 18: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Topical, 2017–2031

    Figure 19: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Intravenous, 2017–2031

    Figure 20: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031

    Figure 21: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031

    Figure 22: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Hospital Pharmacies, 2017–2031

    Figure 23: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Retail Pharmacies, 2017–2031

    Figure 24: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Online Pharmacies, 2017–2031

    Figure 25: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Region, 2020 and 2031

    Figure 26: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Region, 2021–2031

    Figure 27: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 28: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Country, 2020 and 2031

    Figure 29: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Country, 2021–2031

    Figure 30: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Drug Class, 2020 and 2031

    Figure 31: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class, 2021–2031

    Figure 32: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031

    Figure 33: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031

    Figure 34: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031

    Figure 35: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031

    Figure 36: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 37: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

    Figure 38: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 39: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Drug Class, 2020 and 2031

    Figure 40: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class, 2021–2031

    Figure 41: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031

    Figure 42: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031

    Figure 43: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031

    Figure 44: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031

    Figure 45: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 46: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

    Figure 47: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 48: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Drug Class, 2020 and 2031

    Figure 49: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class, 2021–2031

    Figure 50: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031

    Figure 51: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031

    Figure 52: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031

    Figure 53: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031

    Figure 54: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 55: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

    Figure 56: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 57: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Drug Class, 2020 and 2031

    Figure 58: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class, 2021–2031

    Figure 59: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031

    Figure 60: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031

    Figure 61: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031

    Figure 62: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031

    Figure 63: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 64: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

    Figure 65: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 66: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Drug Class, 2020 and 2031

    Figure 67: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class, 2021–2031

    Figure 68: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031

    Figure 69: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031

    Figure 70: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031

    Figure 71: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031

    Figure 72: Market Position Analysis, by Tier and Size of Company

    Figure 73: Bristol-Myers Squibb Revenue (US$ Mn) and Y-o-Y Growth (%), 2017 –2020

    Figure 74: Bristol-Myers Squibb Breakdown of Net Sales (%), by Region/Country, 2020

    Figure 75: Bristol-Myers Squibb R&D Expenses (US$ Mn) 2017–2020

    Figure 76: Novartis AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020

    Figure 77: Novartis AG Breakdown of Net Sales (%), by Region/Country, 2020

    Figure 78: Novartis AG Revenue Breakdown of Net Sales (%), by Business Segment, 2020

    Figure 79: Novartis AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020

    Figure 80: Mesoblast Ltd. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020

    Figure 81: Mesoblast Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020

    Figure 82: Cynata Therapeutics Limited Business Overview

    Figure 83: Incyte Corporation Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020

    Figure 84: Incyte Corporation JAKAFI Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2020

    Figure 85: Incyte Corporation R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020

    Figure 86: Merck & Co. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020

    Figure 87: Merck & Co. Breakdown of Net Sales (%), by Region/Country, 2020

    Figure 88: Merck & Co. Revenue Breakdown of Net Sales (%), by Business Segment, 2020

    Figure 89: Merck & Co. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020

    Figure 90: CSL Limited Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020

    Figure 91: CSL Limited Breakdown of Net Sales (%), by Region/Country, 2020

    Figure 92: CSL Limited Revenue Breakdown of Net Sales (%), by Business Segment, 2020

    Figure 93: CSL Limited R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2020 

Copyright © Transparency Market Research, Inc. All Rights reserved